You are here: Industry Insights > gilead

News List

Gilead aims to produce one million remdesivir treatment courses by 2021 europeanpharmaceuticalreview
April 09, 2020
A letter from the CEO of Gilead reveals how the company plans to scale up production of remdesivir in light of the COVID-19 pandemic.
Gilead initiates two studies of remdesivir for Covid-19 in UK pharmaceutical-technology
April 03, 2020
Gilead Sciences has launched two Phase III clinical trials of its investigational antiviral drug remdesivir in the UK to treat Covid-19 patients.
Mylan and Gilead waive exclusivity for potential Covid-19 therapies pharmaceutical-technology
March 27, 2020
Mylan has waived its exclusive rights to generic Kaletra (lopinavir / ritonavir) in the US to aid wider access in case the medication would be effective Covid-19 therapies.
Gilead Halts Access to Remdesivir contractpharma
March 27, 2020
Gilead’s statement on access to remdesivir outside of clinical trials:Gilead is working to rapidly assess the safety and efficacy of remdesivir as a potential treatment for COVID-19 through multiple ongoing clinical trials.
COVID-19: Gilead deals with ‘overwhelming’ remdesivir demands, Eli Lilly halts trial enrolment pharmatimes
March 25, 2020
As the UK comes to terms with significantly stricter lockdown rules this morning, following prime minister Boris Johnson’s speech last night ...
FDA OKs Gilead’s paediatric hep C drug pharmatimes
March 24, 2020
Gilead has announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Epclusa (sofosbuvir 400mg/velpatasvir 100mg.
Gilead halts emergency access to remdesivir in Covid-19 indication pharmaceutical-technology
March 24, 2020
Gilead Sciences has announced a temporary halt to emergency access to its investigational Covid-19 drug remdesivir due to rising demand.
Gilead's Remdesivir Shows Promise in COVID-19 contractpharma
March 16, 2020
According to a World Health Organizationofficial, Gilead's experimental antiviral drug remdesivir, to date, shows the most promise for treating COVID-19 disease.
Gilead to Acquire Forty Seven for $4.9B contractpharma
March 03, 2020
Will gain lead product candidate magrolimab in clinical development for the treatment of several cancers.
Experimental antiviral Drug Remdesivir recognized as potential treatment for 2019-nCov PharmaSources
February 10, 2020
Remdesivir, an experimental antiviral drug, has been recognized as a potential treatment against the 2019 novel-Coronavirus (2019-nCov) recently outbreaks in China and around the world.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page